Erratum to: Thioridazine specifically sensitizes drug-resistant cancer cells through highly increase in apoptosis and P-gp inhibition (Tumor Biol., (2014), 35, (9831-9838), DOI 10.1007/s13277-014-2278-1);Thioridazine specifically sensitizes drug-resistant cancer cells through highly increase in apoptosis and P-gp inhibition

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 9831-9838

  Choi, Ae Ran ^a   Kim, Ju Hwa ^a   Yoon, Sungpil ^a  

^a National Cancer Center   (South Korea)

Author keywords

Apoptosis; Drug resistant cells; P gp inhibition; Sensitization; Thioridazine; Vinblastine

Indexed keywords

ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; THIORIDAZINE;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FLOW CYTOMETRY; HUMAN; METABOLISM; MOUTH TUMOR; PATHOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; MOUTH NEOPLASMS; P-GLYCOPROTEIN; THIORIDAZINE;

EID: 84922392505     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3836-x     Document Type: Erratum

References (31)

1. Huq ZU. A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychopharmacol. 2004; 24: 220-4.
2. Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvanitis LA. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol. 2002; 22: 121-30.
3. Gil-Ad I, Shtaif B, Levkovitz Y, Nordenberg J, Taler M, Korov I, et al. Phenothiazines induce apoptosis in a b16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. Oncol Rep. 2006; 15: 107-12.
4. Ke XY, Lin Ng VW, Gao SJ, Tong YW, Hedrick JL, Yang YY. Codelivery of thioridazine and doxorubicin using polymericmicelles for targeting both cancer cells and cancer stem cells. Biomaterials. 2014; 35: 1096-108.
5. Lan MY, Yang WL, Lin KT, Lin JC, Shann YJ, Ho CY, Huang CY. Using computational strategies to predict potential drugs for nasopharyngeal carcinoma. Head & neck 2013.
6. Tuynder M, Fiucci G, Prieur S, Lespagnol A, Geant A, Beaucourt S, et al. Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci U S A. 2004; 101: 15364-9.
7. Zhelev Z, Ohba H, Bakalova R, Hadjimitova V, Ishikawa M, Shinohara Y, et al. Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Cancer Chemother Pharmacol. 2004; 53: 267-75.
8. Amson R, Pece S, Lespagnol A, Vyas R, Mazzarol G, Tosoni D, et al. Reciprocal repression between p53 and tctp. NatMed. 2012; 18: 91-9.
9. Nagel D, Spranger S, Vincendeau M, Grau M, Raffegerst S, Kloo B, et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABCDLBCL. Cancer Cell. 2012; 22: 825-37.
10. Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, Russell J, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012; 149: 1284-97.
11. Byun HJ, Lee JH, Kim BR, Kang S, Dong SM, Park MS, et al. Antiangiogenic effects of thioridazine involving the FAK-mTOR pathway. Microvasc Res. 2012; 84: 227-34.
12. Kang S, Dong SM, Kim BR, Park MS, Trink B, Byun HJ, et al. Thioridazine induces apoptosis by targeting the PI3k/AKt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis Int J Program Cell Death. 2012; 17: 989-97.
13. Rho SB, Kim BR, Kang S. A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3k)/AKt pathway in ovarian cancer cells. Gynecol Oncol. 2011; 120: 121-7.
14. Kim JH, Chae M, Choi AR, Sik Kim H, Yoon S. Sp600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition. Eur J Pharmacol. 2014; 723: 141-7.
15. Kim JH, Choi AR, Kim YK, Kim HS, Yoon S. Low amount of salinomycin greatly increases AKt activation, but reduces activated p70s6k levels. Int J Mol Sci. 2013; 14: 17304-18.
16. Kim JH, Choi AR, Kim YK, Yoon S. Co-treatment with the antimalarial drugs mefloquine and primaquine highly sensitizes drugresistant cancer cells by increasing P-gp inhibition. BiochemBiophys Res Commun. 2013; 441: 655-60.
17. Kim JH, Kim TY, Kim HS, Hong S, Yoon S. Lower salinomycin concentration increases apoptotic detachment in high-density cancer cells. Int J Mol Sci. 2012; 13: 13169-82.
18. Yoon S, Kim JH, Lee YJ, Ahn MY, Choi G, KimWK, et al. A novel carbazole derivative, mhy407, sensitizes cancer cells to doxorubicin-, etoposide-, and radiation treatment via DNA damage. Eur J Pharmacol. 2012; 697: 24-31.
19. Kim WK, Kim JH, Yoon K, Kim S, Ro J, Kang HS, et al. Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing g2 arrest. Investig New Drugs. 2012; 30: 1311-8.
20. Szeremy P, Pal A, Mehn D, Toth B, Fulop F, Krajcsi P, et al. Comparison of 3 assay systems using a common probe substrate, calcein AM, for studying P-gp using a selected set of compounds. J Biomol Screen. 2011; 16: 112-9.
21. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008; 10: e19.
22. Chen Q, Ganapathy S, Singh KP, Shankar S, Srivastava RK. Resveratrol induces growth arrest and apoptosis through activation of foxo transcription factors in prostate cancer cells. PLoS One. 2010; 5: e15288.
23. Danson S, Dean E, Dive C, RansonM. IAPS as a target for anticancer therapy. Curr Cancer Drug Targets. 2007; 7: 785-94.
24. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, et al. HER2/PI-3k/AKt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003; 22: 3205-12.
25. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat Rev Comment in Antimicrob Anticancer Chemother. 2007; 10: 13-29.
26. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Re Off J Am Assoc Cancer Res. 2008; 14: 5000-5.
27. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002; 2: 103-12.
28. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther. 2004; 3: 513-9.
29. Solier S, Sordet O, Kohn KW, Pommier Y. Death receptorinduced activation of the Chk2-and histone H2AX-associated DNA damage response pathways. Mol Cell Biol. 2009; 29: 68-82.
30. Kim H, Kim SN, Park YS, Kim NH, Han JW, Lee HY, et al. HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization. Int J Oncol. 2011; 38: 807-12.
31. Kim SN, Kim NH, Park YS, Kim H, Lee S, Wang Q, et al. 7-diethylamino-3(2'-benzoxazolyl)-coumarin is a novel microtubule inhibitor with antimitotic activity in multidrug resistant cancer cells. Biochem Pharmacol. 2009; 77: 1773-9.